Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 78397T202 since 12/18/2024, largest first.
| Filer | % of Class | Filed | ||
|---|---|---|---|---|
|
Vivo Opportunity Fund Holdings, L.P.
13G/A
|
10.0% |
8/14/2026
Event 6/30/2026
|
||
| Vivo Opportunity Fund Holdings, L.P. | 10.0% | |||
| Vivo Opportunity, LLC | 10.0% | |||
| Vivo Opportunity Cayman Fund, L.P. | 10.0% | |||
| Vivo Opportunity Cayman, LLC | 10.0% | |||
|
RA Capital Management, L.P.
13D/A
|
9.9% |
8/10/2026
Event 8/6/2026
|
||
| RA Capital Management, L.P. | 9.9% | |||
| Peter Kolchinsky | 9.9% | |||
| Rajeev Shah | 9.9% | |||
| RA Capital Healthcare Fund, L.P. | 9.9% | |||
|
Commodore Capital LP
13G/A
|
9.9% |
8/14/2026
Event 6/30/2026
|
||
| Commodore Capital LP | 9.9% | |||
| Commodore Capital Master LP | 9.9% | |||
| Robert Egen Atkinson | 9.9% | |||
| Michael Kramarz | 9.9% | |||
|
Balyasny Asset Management L.P.
13G/A
|
9.5% |
8/14/2026
Event 6/30/2026
|
||
| Balyasny Asset Management L.P. | 9.5% | |||
| Bam GP LLC | 9.5% | |||
| Balyasny Asset Management Holdings LP | 9.5% | |||
| Dames GP LLC | 9.5% | |||
| Dmitry Balyasny | 9.5% | |||
|
Biotechnology Value Fund L P
13G/A
|
9.1% |
2/17/2026
Event 12/31/2025
|
||
| Biotechnology Value Fund L P | 5.1% | |||
| BVF I GP LLC | 5.1% | |||
| Biotechnology Value Fund II LP | 3.9% | |||
| BVF II GP LLC | 3.9% | |||
| Biotechnology Value Trading Fund OS LP | 0.5% | |||
| BVF Partners OS Ltd. | 0.5% | |||
| BVF GP Holdings LLC | 8.6% | |||
| BVF Partners L P/IL | 9.1% | |||
| BVF Inc/IL | 9.1% | |||
| Lampert Mark N | 9.1% | |||
|
Caligan Partners LP
13G/A
|
8.8% |
8/14/2026
Event 6/30/2026
|
||
| Caligan Partners LP | 8.8% | |||
| Johnson David Edward | 8.8% | |||
|
Adage Capital Management, L.P.
13G
|
8.4% |
8/12/2026
Event 6/30/2026
|
||
| Adage Capital Management, L.P. | 8.4% | |||
| Robert Atchinson | 8.4% | |||
| Phillip Gross | 8.4% | |||
|
Perceptive Advisors LLC
13G/A
|
7.3% |
8/14/2026
Event 6/30/2026
|
||
| Perceptive Advisors LLC | 7.3% | |||
| Joseph Edelman | 7.3% | |||
| Perceptive Life Sciences Master Fund, Ltd. | 7.3% | |||
| Woodline Partners LP 13G/A | 6.8% |
8/14/2026
Event 6/30/2026
|
||
|
Millennium Management LLC
13G
|
5.1% |
5/1/2026
Event 4/24/2026
|
||
| Millennium Management LLC | 5.1% | |||
| Millennium Group Management LLC | 5.1% | |||
| Israel A. Englander | 5.1% | |||
| Under 5%, checked the "5 percent or less" box, or amended by a later filing (1) | ||||
|
RTW Investments, LP
13G/A
|
3.2% |
2/17/2026
Event 12/31/2025
|
||
| RTW Investments, LP | 3.2% | |||
| Roderick Wong | 3.2% | |||
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2026 Q3 | 1 | 21.0 | $67.00 |
| 2026 Q2 | 92 | 68.4 M | $267 M |
| 2026 Q1 | 83 | 69.6 M | $266 M |
| 2025 Q4 | 48 | 36.3 M | $136 M |
| 2025 Q3 | 35 | 28.0 M | $56.3 M |
| 2025 Q2 | 26 | 1.92 M | $3.37 M |
| 2025 Q1 | 27 | 2.21 M | $2.99 M |
| 2024 Q4 | 27 | 2.65 M | $10.2 M |
| 2024 Q3 | 27 | 3.14 M | $8.48 M |
| 2024 Q2 | 25 | 3.13 M | $9.70 M |
| 2024 Q1 | 28 | 3.34 M | $15.2 M |
| 2023 Q4 | 3 | 8.79 M | $6.06 M |